DOCSLIB.ORG

Charge Master

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Charge Master Epic Charge Code Description Epic Price HC PBB FNA BIOPSY W/O IMAGE GUIDE EA ADDL LESION $587.00 HC FNA BIOPSY W/US GUIDANCE 1ST LESION $1,540.00 HC FNA BIOPSY W/US GUIDANCE EA ADDL LESION $610.25 HC FNA BIOPSY W/FLUORO GUIDANCE 1ST LESION $1,540.00 HC FNA BIOPSY W/FLUORO GUIDANCE EA ADDL LESION $610.25 HC FNA BIOPSY W/CT GUIDANCE 1ST LESION $1,540.00 HC FNA BIOPSY W/CT GUIDANCE EA ADDL LESION $610.25 HC FNA BIOPSY W/MR GUIDANCE 1ST LESION $1,540.00 HC FNA BIOPSY W/MR GUIDANCE EA ADDL LESION $610.25 HC FNA BIOPSY W/O IMAGE GUIDE 1ST LESION $788.00 HC IMAGE-GUIDED CATHETER FLUID COLLECTION DRAINAGE $1,205.50 HC PERQ SFT TISS LOC DEVICE PLMT 1ST LES W/GDNCE $3,652.00 HC PLACEMENT SOFT TISSUE LOCALIZATION DEVICE PERQ EA ADDL W/IMAGE $1,995.00 HC PBB ACNE SURGERY $597.00 HC DRAIN SKIN ABSCESS SIMPLE $441.00 HC DRAIN SKIN ABSCESS COMPLIC $842.75 HC DRAIN PILONIDAL CYST SIMPL $1,552.75 HC REMOVE FOREIGN BODY SIMPLE $842.75 HC REMOVE FOREIGN BODY COMPLIC $1,945.00 HC DRAINAGE OF HEMATOMA/FLUID $1,945.00 HC PUNCTURE DRAINAGE OF LESION $842.75 HC COMPLEX DRAINAGE, WOUND $3,148.75 HC DEBRIDEMENT, INFECTED SKIN, UP TO 10% BSA $1,127.00 HC DEBRIDE ASSOC OPEN FX/DISLO SKIN/MUS/BONE $2,717.50 HC DEBRIDEMENT, SKIN, SUB-Q TISSUE,=<20 SQ CM $938.75 HC DEBRIDEMENT, SKIN, SUB-Q TISSUE,MUSCLE,=<20 SQ CM $1,453.65 HC DEBRIDEMENT BONE 1ST </=20 SQ CM $2,650.00 HC DEBRIDEMENT, SKIN, SUB-Q TISSUE,EACH ADD 20 SQ CM $469.50 HC DEBRIDEMENT, SKIN, SUB-Q TISSUE,MUSCLE,EACH ADD 20 SQ CM $726.80 HC DEBRIDEMENT, SKIN, SUB-Q TISSUE,MUSCLE,BONE,EACH ADD 20 SQ CM $1,450.00 HC TRIM HYPERKERATOTIC SKIN LESION, ONE $1,730.30 HC TRIM BENIGN HYPERKERATOTIC SKIN LESION,2-4 $434.75 HC PARING BENIGN LESION GREATER THAN 4 LESIONS $434.75 HC TANGENTIAL SKIN BX SNGL SHAVE/SCOOP/CURETTE LESION $587.00 HC TANGENTIAL SKIN BX EA ADDL SHAVE/SCOOP/CURETTE LESION $322.00 HC PUNCH SKIN BX SNGL LESION $587.00 HC PUNCH SKIN BX EA ADDL LESION $322.00 HC INCISIONAL SKIN BX SNGL LESION EG WEDGE $1,220.50 HC INCISIONAL SKIN BX EA ADDL LESION $610.25 HC REMOVAL OF SKIN TAGS, UP TO 15 $350.00 HC REMOVAL OF SKIN TAGS, EACH ADD 10 $112.00 HC SHAVE SKIN LESION SINGLE 0.5CM OR < $331.25 HC PBB SHAVE SKIN LESION SINGLE 0.6 - 1.0CM TRUNK,ARM,LEG $331.25 HC SHAVE SKIN LESION SINGLE 1.1 - 2.0CM TRUNK,ARM,LEG $331.25 HC SHAVE SKIN LESION SINGLE >2.0CM TRUNK,ARM,LEG $431.25 HC SHAVE SKIN LESION SINGLE 0.5CM/< SCALP,NECK,HAND,FEET,GENITALIA $331.25 HC SHAVE SKIN LESION SINGLE 0.6 - 1.0CM SCALP,NECK,HAND,FEET GENITALIA $331.25 HC SHAVE SKIN LESION SINGLE 1.1 - 2.0CM SCALP,NECK,HAND,FEET,GENETALIAPOD $331.25 HC SHAVE SKIN LESION SINGLE > 2.0 CM SCALP,NECK,HAND,FEET,GENITALIA $431.25 HC SHAVE SKIN LESION SINGLE =/<0.5CM FACE,EAR,EYELID,NOSE,LIPS,MUC MEM $331.25 HC SHAVE SKIN LESION SINGLE 0.6 - 1.0CM FACE,EAR,EYELID,NOSE,LIP,MUC MEM $331.25 HC SHAVE SKIN LESION SINGLE 1.1 - 2.0CM FACE,EAR,EYELID,NOSE,LIP,MUC MEM $431.25 HC SHAVE SKIN LESION SINGLE > 2.0 CM FACE,EAR,EYELID,NOSE,LIP,MUC MEM $431.25 HC PBB EXC BENIGN LESION +MARGIN <0.5CM TRNK/EXTR $1,736.50 HC EXC SKIN BENIG 0.6-1 CM TRUNK,ARM,LEG $1,250.00 HC PBB EXC SKIN BENIG >4 CM TRUNK,ARM,LEG $2,850.00 HC EXC BENIGN LESION =<1.5CM SCALP,NECK,HAND,FEET,GENITALIA $2,240.00 HC PBB EXC SKIN BENIG 0.6-1 CM REMAINDR BODY $1,250.00 HC PBB EXC SKIN BENIGN 1.1-2 CMS SCALP,NECK,HAND,FEET,GENITALIA $2,240.00 HC PBB EXC SKIN BENIG 2.1-3 CM REMAINDR BODY $2,250.00 HC PBB EXC BENIGN LESION =<0.5CM FACE/EYL/E/N/LIP/MM $1,250.00 HC PBB EXC BENIGN LESION 0.6 TO 1.0CM FACE/EYL/E/N/LIP/MM SKIN $1,250.00 HC PBB EXC BENIGN LESION 1.1-2.0CM FACE/EYELID/EAR/NOSE/LIP/MUC MEM $1,250.00 HC PBB EXCISION BENIGN LESIONS >4.0CM FACE,EAR,EYELID,NOSE,LIP,MUC MEM $3,179.25 HC EXC MALIG LESION =< 0.5CM TRNK/ARMS/LEGS $1,250.00 HC PBB EXC SKIN MALIG 0.6-1 CM TRUNK,ARM,LEG $1,192.00 HC PBB EXC SKIN MALIG 1.1-2 CM TRUNK,ARM,LEG $1,250.00 HC PBB EXC SKIN MALIG 2. 1-3 CM TRUNK,ARM,LEG $1,050.00 HC PBB EXC MALIG LESION SCALP/NECK/HAND/FEET/GEN 1.1-2.0CM $1,402.50 HC PBB EXC SKIN MALIG 3.1-4 CM SCALP,NECK,HAND,FEET,GENIT $1,945.00 HC PBB EXC MALIG LESION =/< 0.5CM FACE,EAR,EYLID,NOSE,LIP $1,250.00 HC PBB EXC MALIGNANT LESION 0.6-1.0CM FACE,EAR,EYELID,NOSE,LIP $1,736.50 HC PBB EXC MALIGNANT LESION 0.1 TO 2.0CM FACE,EAR,EYELID,NOSE,LIP $1,736.50 HC PBB EXC SKIN MALIG 2.1-3 CM FACE,EAR,EYELID,NOSE,LIP $2,240.00 HC PBB EXC SKIN MALIG 3.1-4 CM FACE,EAR,EYELID,NOSE,LIP $2,240.00 HC PBB EXC SKIN MALIG >4 CM FACE,EAR,EYELID,NOSE,LIP $2,898.65 HC TRIM NONDYSTROPHIC NAILS $839.50 HC DEBRIDE NAIL ANY METHOD 1-5 OST $863.40 HC DEBRIDEMENT OF NAILS, 6 OR MORE $863.40 HC REMOVAL OF NAIL PLATE $441.25 HC REMOVAL OF NAIL PLATE EACH ADDL $220.50 HC DRAIN BLOOD FROM UNDER NAIL $165.00 HC REMOVAL OF NAIL BED $843.00 HC BIOPSY OF NAIL UNIT $778.75 HC RECONSTRUC OF NAIL BED $745.55 HC EXCISION OF NAIL FOLD, TOE $525.50 HC INJECTION INTO SKIN LESIONS, UP TO 7 $331.25 HC INJECT INTRALESIONAL MORE THAN 7 LESIONS $331.25 HC IMPLANON REMOVAL CAPSULE $925.00 HC INSERT NEXPLANON NONBIO DRUG $334.00 HC REMOVE NONBIO DRUG NEXPLANON $839.50 HC REMOVE/REINSERT NONBIO DRUG NEXPLANON $508.50 HC REPAIR SUPERFICIAL WND SIMPLE =/< 2.5CM SCALP,N,AX,GEN,TRUNK,EXTREM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 2.6-7.5CM SCALP,N,AX,GEN,TRUNK,EXTREM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 7.6-12.5CM SCALP,N,AX,GEN,TRUNK,EXTREM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 12.6-20CM SCALP,N,AX,GEN,TRUNK,EXTREM $525.50 HC REPAIR SUPERFICIAL WND SIMPLE 20.1-30CM SCALP,N,AX,GEN,TRUNK,EXTREM $525.50 HC REPAIR SUPERFICIAL WND SIMPLE >30CM SCALP,N,AX,GEN,TRUNK,EXTREM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE =/< 2.5CM FACE,EAR,EYELID,NOSE,LIP,MM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 2.6-5.0CM FACE,EAR,EYEL,NOSE,LIP,MM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 5.1-7.5CM FACE,EAR,EYEL,NOSE,LIP,MM $331.25 HC REPAIR SUPERFICIAL WND SIMPLE 7.6-12.5CM FACE,EAR,EYEL,NOSE,LIP,MM $331.25 HC REPAIR SUPERFICIAL WD SIMPLE 12.6-20CM FACE,EAR,EYEL,NOSE,LIP,MM $525.50 HC REPAIR SUPERFICIAL WND SIMPLE 20.1-30CM FACE,EAR,EYEL,LIP,NOSE,MM $525.50 HC REPAIR SUPERFICIAL WND SIMPLE >30CM FACE,EAR,EYEL,LIP,NOSE,MM $331.25 HC CLOSURE SUPERF WND DEHIS SIMPLE $745.55 HC CLOSURE SUPERFICIAL SPLIT WND W/PACKING $525.50 HC REPAIR WND INTERM <2.5CM SCALP,AX,TRUNK,EXTREM $750.00 HC REPAIR INTMD WND 2.6-7.5CM SCALP,AX,TRUNK,EXTREM $750.00 HC REPAIR WND INTMD 7.6-12.5CM SCALP,AX,TRUNK, EXTREM $750.00 HC REPAIR INTMD WND 12.6-20CM SCALP,AX,TRUNK,EXTREM $750.00 HC REPAIR INTRMD WND 20.0-30CM SCALP,AX,TRUNK,EXTREM $750.00 HC REPAIR INTMD WND >30CM SCALP,AX,TRUNK,EXTREM $2,450.00 HC REPAIR INTMD WND =/<2.5CM NECK,HAND,FEET,GENT $750.00 HC REPAIR INTMD WND 2.6-7.5CM NECK,HAND,FEET,GENT $750.00 HC REPAIR INTRMD WND 7.6-12.5 CM NECK,HAND,FEET,GENT $750.00 HC REPAIR INTMD WND 12.6-20CM NECK,HAND,FEET,GENT $750.00 HC REPAIR INTMD 20.1-30CM NECK,HAND,FEET,GENT $750.00 HC REPAIR INTMD WND >30CM NECK,HAND,FEET,GENT $2,450.00 HC REPAIR INTRMD WND =/< 2.5CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND 2.5-5CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND 5.1-7.5CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND 7.6-12.5CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND 12.6-20CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND 20.1-30CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR INTRMD WND >30CM FACE,EAR,EYEL,NOSE,LIP,MM $750.00 HC REPAIR COMPLEX WND 1.1-2.5CM TRUNK $910.75 HC REPAIR COMPLEX WND 2.6-7.5CM TRUNK $910.75 HC REPAIR COMPLEX WND EA ADD =<5CM TRUNK $256.50 HC REPAIR COMPLEX WND 1.1-2.5CM SCALP,ARM,LEG $910.75 HC REPAIR COMPLEX WND 2.6-7.5CM SCALP,ARM,LEG $910.75 HC REPAIR COMPLEX WND =/<5CM EA ADDL SCALP,ARM,LEG $256.50 HC REPAIR CMPLEX WND 1.1-2.5CM HEAD,FACE,HAND $910.75 HC REPAIR CMPLEX WND 2.6-7.5CM HEAD,FACE,HAND $910.75 HC REPAIR COMPLEX WND EA ADDL =/>5CM FACE,HAND,FEET $424.75 HC RECMPL WND LID,NOS,EAR 1.1-2.5 CM $910.75 HC RECMPL WND LID,NOS,EAR 2.5-7.5 CM $910.75 HC REPAIR WND COMPLEX EA ADD =/<5CM EYEL,NOSE,EAR,LIP $256.50 HC REPAIR WND SECONDARY COMPLEX/ENTENS DEHSN $2,450.00 HC WOUND PREP, PED, TRK/ARM/LG 1ST 100 CM $2,450.00 HC WOUND PREP, PED, TRK/ARM/LG ADDL 100 CM $817.00 HC WND PREP PED, FACE/NCK/HND/FT/GEN 1ST 100 CM $940.50 HC APPL SKIN SUB INIT =/< 25SQ CM TRUNK/ARM/LEG FC $2,450.00 HC APPLY SKIN SUB EA ADD =/< 25SQ CM TRUNK/ARM/LEG FC $1,224.55 HC APPLY SKIN SUB INIT 100SQ CM TRUNK,ARM,LEG $4,470.75 HC APPLY SKIN SUB ADD 100SQ CM TRUNK/ARM/LEG $2,800.00 HC APPLY SKIN SUB INIT 25SQ CM FACE,HAND,NECK,HF,GENT $2,450.00 HC APPLY SKIN SUB ADD 25SQ CM FACE,SCALP,NK,HF,G,DIGITS $1,224.55 HC APPLY SKIN SUB INIT 100SQ CM F,S,NK,HF,GEN,DIGITS $2,450.00 HC APPLY SKIN SUB ADD 100SQ CM F,S,NK,HF,GEN,DIGITS $1,224.55 HC REMOVE SUTURES W/ANESTH SAME SURGEON $745.55 HC REMOVE SUTURES W/ANESTH DIFF SURGEON $2,434.00 HC DRESSING CHNG NOT FOR BURN W/ANESTH/SED $745.55 HC INITIAL RX BURN(S) 1ST DEGREE $178.50 HC DRESS/DEBRID <5% BODY SM $491.25 HC DRESS/DEBRID 5-10% BODY MED $491.25 HC DRESS/DEBRID PART THCK +10% BODY LG $938.75 HC DESTRUC BENIGN/PREMAL,FIRST LESION $169.00 HC PBB DESTRUCT BENIGN/PREMAL 2ND-14 LESIONS $133.00 HC DESTRUC BENIGN/PREMAL,15+ LESIONS $310.75 HC DESTRUCTION OF CUTANEOUS VASC LESIONS <10SQ $525.50 HC DESTRUCT CUTANEOUS VASC LESIONS 10-50SQ CM $863.40 HC DESTRUCT CUTANEOUS VASC LESIONS +50SQ CM $2,450.00 HC DESTRUCTION BENIGN LESIONS UP TO 14 $863.40 HC DESTRUCTION BENIGN LESIONS 15 OR MORE $331.25 HC CHEMICAL CAUTERIZATION OF GRANULATION TISSUE $434.75 HC PBB DESTRUCT MALIGNANT LESION =/<0.5 TRUNK,EXTREM $331.25 HC PBB DESTRUCT MALIGNANT LESION 0.6-1.0 TRUNK/EXTREM $331.25 HC PBB DESTRUCT MALIG LESION
Load more

Recommended publications
  • Large Pink Inclusions in Multiple Myeloma Cells
    Journal of Blood Disorders, Symptoms & Treatments Case Report Large Pink Inclusions in Multiple Myeloma Cells This article was published in the following Scient Open Access Journal: Journal of Blood Disorders, Symptoms & Treatments Received July 28, 2017; Accepted August 05, 2017; Published August 11, 2017 Juan Zhang1, Mingyong Li1*, Xianyong Jiang2 and Yuan He1 Abstract 1Clinical Laboratory of Sichuan Academy of Medical Objective: Several intracytoplasmic morphological changes in the plasma cells of Science & Sichuan Provincial People’s Hospital, multiple myeloma have been described previously, especially the Auer rod-like inclusions, Chengdu, Sichuan, China but large pink inclusions have not been reported yet. In this paper, we intend to report a rare 2 Haematology Bone Marrow Inspection laboratory case of inclusions in multiple myeloma. of Peking Union Medical College Hospital, Beijing, China Methods: Bone marrow aspiration from the right superior iliac spine was examined twice. Cells were stained with “Wright-Giemsa” method and also analyzed by flow cytometry, immunohistochemical staining and fluorescence in situ hybridization (FISH). Bone scan demonstrated bilateral ribs, thoracic vertebrae, with multiple low density shadows, which was confirmed subsequently as a lytic lesion on CT scanning. Complete blood count, serum chemistry and coagulation tests were also examined. Results: Bone marrow aspirate from the right superior iliac spine at the time of myeloma diagnosis showed about 58.5% of all nucleated cells being plasma cells, of which many had large pink intracytoplasmic inclusions. Repeat bone marrow biopsy later showed persistence of these morphological findings. All of Flow cytometry, immunohistochemistry and FISH examination support the diagnosis of multiple myeloma. Conclusion: This is the first time to report a multiple myeloma case with such giant pink inclusions.
    [Show full text]
  • Section 8: Hematology CHAPTER 47: ANEMIA
    Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited.
    [Show full text]
  • Method Development and Validation of Vitamin D2 and Vitamin D3 Using Mass Spectrometry
    Method Development and Validation of Vitamin D2 and Vitamin D3 Using Mass Spectrometry Devon Victoria Riley A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science University of Washington 2016 Committee: Andrew Hoofnagle Geoffrey Baird Dina Greene Program Authorized to Offer Degree: Laboratory Medicine ©Copyright 2016 Devon V. Riley ii University of Washington Abstract Method Development and Validation of Vitamin D2 and Vitamin D3 Using Mass Spectrometry Devon V. Riley Chair of the Supervisory Committee: Associate Professor Andrew Hoofnagle, MD, PhD Vitamin D has long been known to maintain bone health by regulating calcium and phosphorous homeostasis. In recent years, scientists have discovered additional physiological roles for vitamin D. The complex interaction between the active vitamin D hormone and its metabolic precursors continues to be a rich area of research. Fundamental to this research is the availability of accurate and precise assays. Few published assays for vitamins D2 and D3 have contained sufficient details on method validation or performance characteristics. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay developed for this thesis has undergone a rigorous validation and proven to yield a sensitive and specific method that exceeds the capabilities of all previously published methods. Developing and validating a novel assay is often complicated by the lack of established acceptability standards. This thesis explores this challenge, specifically for establishing meaningful interpretations and qualification standards of the lower limit of the measuring interval. Altogether, future research focused on vitamins D2, D3 and the Vitamin D pathway can benefit from this robust LC-MS/MS assay and the associated quality parameters outlined in this thesis.
    [Show full text]
  • Evaluation of Prolonged Surface Activated Coagulation Time
    Biomedical Science Faculty of Health and Society Malm¨oUniversity SE-205 06 Malm¨o Sweden Master programme in Biomedical Surface Science http://edu.mah.se/en/Program/VABSE Evaluation of prolonged surface activated coagulation time Master degree thesis, 30 ECTS Author: Amalie Jesting Supervisors: Sebastian Bj¨orklund,PhD, Lecturer, Malm¨oUniversity Jens Peter Gøtze, MD, DMSc Professor, Chief-Physician, Rigshospitalet Søren Frank Jørgensen, MSc, Senior Lecturer, Metropolitan University College August 2018 MALMO¨ UNIVERSITY Abstract Faculty of Health and Society Master programme in Biomedical Surface Science Evaluation of prolonged surface activated coagulation time by Amalie Jesting Background: Blood coagulation is an essential defense mechanism to prevent bleeding. Disorders in the coagulation system can be severe and blood tests measuring the blood's ability to coagulate are important. Activated partial thromboplastin time (APTT) is a blood test that measures blood coagulation time. An abnormal prolonged APTT can both be associated with a bleeding tendency or a risk of thrombosis. Additional blood tests are needed to discover the cause of a prolonged APTT. One potential test is the APTT mixing study, which can separate samples with and without inhibitors. The aim of this project is to investigate how the cause of a prolonged APTT is evaluated today and to examine if it is possible to indicate the cause of a prolonged APTT using the APTT mixing study performed on routine samples. The goal is to be able to indicate the cause of a prolonged APTT immediately when is it first discovered. This will save time and help guide the physicians in their work with the patient.
    [Show full text]
  • Research Article
    z Available online at http://www.journalcra.com INTERNATIONAL JOURNAL OF CURRENT RESEARCH International Journal of Current Research Vol. 8, Issue, 12, pp.42994-42999, December, 2016 ISSN: 0975-833X RESEARCH ARTICLE PLASMA CELLS IN HEALTH AND DISEASE *Karuna Kumari, Shwetha Nambiar, K., Vanishree C Haragannavar, Dominic Augustine, Sowmya, S. V. and Roopa S Rao Faculty of Dental Sciences, M.S. Ramaiah University of Applied Sciences, Bangalore, Karnataka ARTICLE INFO ABSTRACT Article History: Plasma cells are the only cells that sustain antibody production and hence are an essential part of immune system. In the bone marrow plasma cells produce immunoglobulins which assure long-term Received 03rd September, 2016 Received in revised form humoral immune protection and in the mucosa-associated lymphoid tissues (MALT) plasma cells 16th October, 2016 secrete IgA which protect the individual from pathogens invasion. This review illustrates plasma cell Accepted 25th November, 2016 development and their role in both health and disease. Published online 30th December, 2016 Key words: Plasma cell, Immunoglobulin, B cells. Copyright©2016, Karuna Kumari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Citation: Karuna Kumari, Shwetha Nambiar, K., Vanishree C Haragannavar, Dominic Augustine, Sowmya, S. V. and Roopa S Rao, 2016. “Plasma cells in health and disease”, International Journal of Current Research, 8, (12), 42994-42999. INTRODUCTION cytoplasm of the PCs contains large amount of rough endoplasmic reticulum (rER) and Golgi apparatus. The Plasma Cells (PCs) are non-dividing, effectors cells that cytoplasm of PC displays strong basophilia due to presence of represent the final stage of B cell differentiation.
    [Show full text]
  • Clinical Usefulness of Serum Procalcitonin Level in Distinguishing Between Kawasaki Disease and Other Infections in Febrile Children
    Original article LeeKorean NY, Jet Pediatr al. • Serum 2017;60(4):112-117 procalcitonin level between Kawasaki disease and other infections https://doi.org/10.3345/kjp.2017.60.4.112 pISSN 1738-1061•eISSN 2092-7258 Korean J Pediatr Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children Na Hyun Lee, MD1, Hee Joung Choi, MD1, Yeo Hyang Kim, MD2 1Department of Pediatrics, Keimyung University School of Medicine, Daegu, 2Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea Purpose: The aims of this study were to compare serum procalcitonin (PCT) levels between febrile Corresponding author: Yeo Hyang Kim, MD, PhD children with Kawasaki disease (KD) and those with bacterial or viral infections, and assess the clinical Department of Pediatrics, Kyungpook National Uni- versity School of Medicine, 680 Gukchaebosang-ro, usefulness of PCT level in predicting KD. Jung-gu, Daegu 41944, Korea Methods: Serum PCT levels were examined in febrile pediatric patients admitted between August 2013 Tel: +82-53-200-5720, and August 2014. The patients were divided into 3 groups as follows: 49 with KD, 111 with viral infec- Fax: +82-53-425-6683, tions, and 24 with bacterial infections. E-mail: [email protected] Results: The mean PCT level in the KD group was significantly lower than that in the bacterial infection Received: 26 August, 2016 group (0.82±1.73 ng/mL vs. 3.11±6.10 ng/mL, P=0.002) and insignificantly different from that in Revised: 27 October, 2016 the viral infection group (0.23±0.34 ng/mL,P=0.457).
    [Show full text]
  • Hereditary Spherocytosis: Clinical Features
    Title Overview: Hereditary Hematological Disorders of red cell shape. Disorders Red cell Enzyme disorders Disorders of Hemoglobin Inherited bleeding disorders- platelet disorders, coagulation factor Anthea Greenway MBBS FRACP FRCPA Visiting Associate deficiencies Division of Pediatric Hematology-Oncology Duke University Health Service Inherited Thrombophilia Hereditary Disorders of red cell Disorders of red cell shape (cytoskeleton): cytoskeleton: • Mutations of 5 proteins connect cytoskeleton of red cell to red cell membrane • Hereditary Spherocytosis- sphere – Spectrin (composed of alpha, beta heterodimers) –Ankyrin • Hereditary Elliptocytosis-ellipse, elongated forms – Pallidin (band 4.2) – Band 4.1 (protein 4.1) • Hereditary Pyropoikilocytosis-bizarre red cell forms – Band 3 protein (the anion exchanger, AE1) – RhAG (the Rh-associated glycoprotein) Normal red blood cell- discoid, with membrane flexibility Hereditary Spherocytosis: Clinical features: • Most common hereditary hemolytic disorder (red cell • Neonatal jaundice- severe (phototherapy), +/- anaemia membrane) • Hemolytic anemia- moderate in 60-75% cases • Mutations of one of 5 genes (chromosome 8) for • Severe hemolytic anaemia in 5% (AR, parents ASx) cytoskeletal proteins, overall effect is spectrin • fatigue, jaundice, dark urine deficiency, severity dependant on spectrin deficiency • SplenomegalSplenomegaly • 200-300:million births, most common in Northern • Chronic complications- growth impairment, gallstones European countries • Often follows clinical course of affected
    [Show full text]
  • A Life-Threatening Case of Pregnancy-Related Atypical
    Puri et al. BMC Nephrology (2020) 21:488 https://doi.org/10.1186/s12882-020-02100-4 CASE REPORT Open Access A life-threatening case of pregnancy- related atypical Haemolytic uremic syndrome and successful treatment with Eculizumab Prianka Puri1,2* , Anida Hanxhiu1, Daniel V. O’Hara1,3, Danny Hsu4 and Mirna Vucak-Dzumhur1,5 Abstract Background: Pregnancy-related Atypical Haemolytic Uremic Syndrome (P-aHUS) is a rare condition affecting genetically predisposed women during pregnancy. It is often difficult to diagnose and has a significant impact on maternal and foetal outcomes. It is characterised by microangiopathic haemolytic anaemia and kidney injury from thrombotic microangiopathy. Case presentation: A 27-year-old female of Lebanese descent presented at 36 weeks’ gestation with foetal death in-utero (FDIU) with placental abruption on a background of previously normal antenatal visits. She was coagulopathic and anaemic with anuric acute kidney injury, requiring emergency Caesarean section, intubation and dialysis. Her coagulopathy rapidly resolved, however, her anaemia and renal dysfunction persisted. A diagnosis of P-aHUS was made, and she was empirically treated with Eculizumab. Her ADAMTS13 level was normal, effectively excluding thrombotic thrombocytopenic purpura. Within 2 weeks of treatment her haematological parameters improved, and her renal function began to recover and within 2 months she became dialysis independent. Conclusion: This case highlights the challenges of a timely diagnosis of P-aHUS from other pregnancy-related diseases. Although our patient is dialysis-independent, her risk of relapse remains high with subsequent pregnancies. Currently we are awaiting her genetic sequencing to complete her assessment for underlying mutations and are determining the safest approach to a future planned pregnancy.
    [Show full text]
  • 25 May 7, 2014
    Joint Pathology Center Veterinary Pathology Services Wednesday Slide Conference 2013-2014 Conference 25 May 7, 2014 ______________________________________________________________________________ CASE I: 3121206023 (JPC 4035610). Signalment: 5-week-old mixed breed piglet, (Sus domesticus). History: Two piglets from the faculty farm were found dead, and another piglet was weak and ataxic and, therefore, euthanized. Gross Pathology: The submitted piglet was in good body condition. It was icteric and had a diffusely pale liver. Additionally, petechial hemorrhages were found on the kidneys, and some fibrin was present covering the abdominal organs. Laboratory Results: The intestine was PCR positive for porcine circovirus (>9170000). Histopathologic Description: Mesenteric lymph node: Diffusely, there is severe lymphoid depletion with scattered karyorrhectic debris (necrosis). Also scattered throughout the section are large numbers of macrophages and eosinophils. The macrophages often contain botryoid basophilic glassy intracytoplasmic inclusion bodies. In fewer macrophages, intranuclear basophilic inclusions can be found. Liver: There is massive loss of hepatocytes, leaving disrupted liver lobules and dilated sinusoids engorged with erythrocytes. The remaining hepatocytes show severe swelling, with micro- and macrovesiculation of the cytoplasm and karyomegaly. Some swollen hepatocytes have basophilic intranuclear, irregular inclusions (degeneration). Throughout all parts of the liver there are scattered moderate to large numbers of macrophages (without inclusions). Within portal areas there is multifocally mild to moderate fibrosis and bile duct hyperplasia. Some bile duct epithelial cells show degeneration and necrosis, and there is infiltration of neutrophils within the lumen. The limiting plate is often obscured mainly by infiltrating macrophages and eosinophils, and fewer neutrophils, extending into the adjacent parenchyma. Scattered are small areas with extra medullary hematopoiesis.
    [Show full text]
  • Mixing Studies
    Welcome Jim DeMase, Senior National Technical Sales Manager Sunday March 19, 2017/CAMLT/Kaiser Regional Reference Lab Welcome Your Presenter Today Jim DeMase, Senior National Technical Sales Manager, Precision BioLogic Account Manger for Western and Central USA and British Columbia, Alberta, Saskatchewan and Manitoba CANADA. H A L L A Hemostasis Is Unique-The Cascade, the Diseases and the Tests-All Mixed Up Part 1- What is Hemostasis Part 2- Intro to Hemophilia Part 3- Mixing Studies Objectives 1. Describe the stages of hemostasis as well as common bleeding and thrombotic disorders. 2. Explain the types of hemophilia, symptoms, diagnosis and common treatments. 3. Relate the methods and clinical application for a mixing study and the steps to perform one. What is Hemostasis? Pathology Study of diseases Especially the structural and functional changes (to the body) caused by the diseases Many disciplines Biochemistry Blood Transfusion Services Histology Microbiology Hematology Hematology Science of blood and its diseases Sub-disciplines: Immunology Microscopy Molecular Biology Hemostasis (Coagulation) Hemostasis The process of stopping bleeding Greek roots heme, blood + stasis, halt = halt of the blood Blood Red viscous liquid in arteries, veins and capillaries Pumped by the heart Irrigates every tissue Transport of gases, nutritive materials and elements for immunity Blood Leading the way in experimental and clinical research in hematology Blood composition Cellular Red cells: hemoglobin White cells: neutrophils, monocytes, lymphocytes Platelets: small cells, essential role in prevention of blood loss Liquid Plasma: yellow liquid, composed mainly of lightly salted water containing nutritional materials, waste products and numerous different proteins Proteins in the Plasma Albumin Globulins Coagulation proteins Procoagulant (e.g.
    [Show full text]
  • Outpatient Laboratory Requisition
    Yale-New Haven Hospital Department of Laboratory Medicine Outpatient Laboratory Requisition 20 York Street, New Haven, Connecticut 06510-3202 · 203-688-3670 · 1-800-305-3278 DATE: _____/____/_____ Unit #___________________________ Visit #_______________________________ Patient Name _______________________________________________________________________________ (Last, First, Middle Initial) Date of Birth______/_____/______ ❑ Female ❑ Male Patient Telephone: (______) ________-_____________ Address ___________________________________________________________________________________ (Street, City, State, Zip) ❑ Mr. Insured’s Name ❑ M r s . _______________________________________________________________________ Ms. Insured’s I.D. # __❑____________________________________________________________________________ Payor Number ______________________________________________________________________________ Primary Insurance: Name & State _______________________________________________________________ Relationship to patient: ❑ Self ❑ Spouse ❑ Child ❑ Other __________________________________________ Group # _________________________________ Insured’s Employer ________________________________ Diagnosis / ICD 9 Code _________________________ TIME DRAWN: ________ ❑ YNHH Blood Draw ❑ Fasting Specimen Type: ❑ Blood ❑ Urine ❑ Other_______________________ ❑ CSF ❑ Fluid____________ ❑ Bone Marrow ❑ Call / ❑ Fax Results ❑ Timed Urine Date Collected _______ Time Collected ________ To:________________________________ CC: X TEST NAME SCC CODE X TEST NAME SCC CODE
    [Show full text]
  • HIV Infection and AIDS
    G Maartens 12 HIV infection and AIDS Clinical examination in HIV disease 306 Prevention of opportunistic infections 323 Epidemiology 308 Preventing exposure 323 Global and regional epidemics 308 Chemoprophylaxis 323 Modes of transmission 308 Immunisation 324 Virology and immunology 309 Antiretroviral therapy 324 ART complications 325 Diagnosis and investigations 310 ART in special situations 326 Diagnosing HIV infection 310 Prevention of HIV 327 Viral load and CD4 counts 311 Clinical manifestations of HIV 311 Presenting problems in HIV infection 312 Lymphadenopathy 313 Weight loss 313 Fever 313 Mucocutaneous disease 314 Gastrointestinal disease 316 Hepatobiliary disease 317 Respiratory disease 318 Nervous system and eye disease 319 Rheumatological disease 321 Haematological abnormalities 322 Renal disease 322 Cardiac disease 322 HIV-related cancers 322 306 • HIV INFECTION AND AIDS Clinical examination in HIV disease 2 Oropharynx 34Neck Eyes Mucous membranes Lymph node enlargement Retina Tuberculosis Toxoplasmosis Lymphoma HIV retinopathy Kaposi’s sarcoma Progressive outer retinal Persistent generalised necrosis lymphadenopathy Parotidomegaly Oropharyngeal candidiasis Cytomegalovirus retinitis Cervical lymphadenopathy 3 Oral hairy leucoplakia 5 Central nervous system Herpes simplex Higher mental function Aphthous ulcers 4 HIV dementia Kaposi’s sarcoma Progressive multifocal leucoencephalopathy Teeth Focal signs 5 Toxoplasmosis Primary CNS lymphoma Neck stiffness Cryptococcal meningitis 2 Tuberculous meningitis Pneumococcal meningitis 6
    [Show full text]